Compare IRON & ARCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRON | ARCB |
|---|---|---|
| Founded | 2017 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trucking Freight/Courier Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.7B |
| IPO Year | 2020 | 1994 |
| Metric | IRON | ARCB |
|---|---|---|
| Price | $68.20 | $129.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | $103.18 | ★ $122.75 |
| AVG Volume (30 Days) | ★ 426.0K | 315.9K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 0.38% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,657,864,000.00 |
| Revenue This Year | N/A | $7.00 |
| Revenue Next Year | $283.52 | $5.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 12.56 |
| 52 Week Low | $40.00 | $59.43 |
| 52 Week High | $99.50 | $135.10 |
| Indicator | IRON | ARCB |
|---|---|---|
| Relative Strength Index (RSI) | 51.91 | 64.13 |
| Support Level | $58.13 | $115.28 |
| Resistance Level | $71.53 | $135.10 |
| Average True Range (ATR) | 3.23 | 4.65 |
| MACD | -0.17 | 0.22 |
| Stochastic Oscillator | 46.09 | 94.52 |
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
ArcBest Corp is an integrated logistics company that leverages technology and a full suite of shipping and logistics solutions to meet customers' supply chain needs. The company has two reportable operating segments: Asset-Based, which generates maximum revenue, and Asset-Light. The Asset-Based segment's operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed less-than-truckload services. The Asset-Light segment represents the company's offerings in ground expedite, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.